#United States #New York #Levi & Korsinsky #Securities Class Action #GeneDx Holdings

GeneDx Holdings Under Scrutiny: A Closer Look at the Securities Class Action

Recently, GeneDx Holdings Corp. has found itself at the center of a potential securities class action, alerting investors to a series of events culminating in significant stock losses. The law firm Levi & Korsinsky, LLP has issued a reminder to investors regarding the need to be aware of their rights, especially concerning potential recovery of losses incurred during a specific period — from April 16, 2025 to May 4, 2026.

The Heart of the Allegations

At the core of this legal action are two senior executives: CEO Katherine Stueland and CFO Kevin Feeley. Both have been named as individual defendants alongside the company itself. The allegations stem from the assertion that these executives played pivotal roles in influencing the company's image and the information provided to analysts and institutional investors, ultimately controlling the narrative that surrounded GeneDx Holdings’ performance.

As per reports, shareholders witnessed a striking decline in the value of their investments, with GeneDx shares dropping an alarming 49.20% during the cited timeframe. This decline, translating to a loss of $33.42 per share, was predominantly attributed to the company's announcement of a $31.2 million impairment charge alongside a drastic $65 million cut in its full-year revenue guidance.

What the Lawsuit Entails

The securities class action comprises key claims under Section 20(a) of the Securities Exchange Act of 1934. This section targets individuals within a company who wield control and are thus held responsible for the company’s breaches of federal securities laws. The lawsuit claims that both Stueland and Feeley, due to their executive roles, were in the know regarding the challenges facing the company's subsidiary, Fabric Genomics, particularly its integration and overall viability.

Key Responsibilities and Allegations

The complaint outlines how both executives had access to crucial information, including public statements made before their release, giving them the leverage to prevent potential inaccuracies. Their active participation in earnings calls, where misleading statements were allegedly made about the performance and revenue potential of the Fabric acquisition, is also a significant focus. Besides, the complaint emphasizes their apparent disregard for the discrepancy between public affirmations and the company’s actual performance metrics.

Equally concerning are the implications of the Sarbanes-Oxley Act, underscoring the requirement for certification of company filings and the implications of disclosing information that could mislead shareholders. The lawsuit highlights how, during a timeframe of known adverse performance results, they signed certifications asserting the accuracy of the statements made in SEC filings.

Looking Ahead: The Deadline Approaches

For impacted investors, it’s crucial to act before August 3, 2026, the cut-off date for appointing a lead plaintiff within this case. While it is not mandatory for all class members to take immediate action, it is advisable to prepare by gathering necessary documents, such as brokerage records detailing purchase dates, share quantities, and prices paid. Moreover, it’s important to note that even those who have sold their shares may still be eligible to join the recovery efforts based on their purchasing activities during the class period.

As public scrutiny intensifies and legal proceedings unfold, GeneDx investors are advised to stay informed and proactive. The compliance mechanisms within federal securities laws serve as an essential safeguard for holders of such securities, ensuring that corporate malfeasance can be addressed effectively.


For more information, investors can reach out to Levi & Korsinsky, which specializes in handling such securities litigation, offering no-cost evaluations to determine the recoverable losses for impacted parties.